Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
The subtype that comprises 5 percent of HIV-1 infections globally traveled from Africa to Thailand where it was identified in 1989. From there, it spread around […]
A program that screened more than 7000 inmates for tuberculosis at four South Africa correctional facilities showed that a large number of inmates could be diagnosed […]
PrEP: Risk of resistance to antiretroviral drugs used to prevent infection is lower than thought, study finds
Highest risk of resistance found in those starting drugs with undiagnosed infection, pointing to importance of screening The landmark study that found preventive use of antiretroviral […]
“I don’t want to say ‘what has been allowed to occur, so I’ll backtrack, and say, ‘what has occurred’ . . .” Dr. Dan Lucey is […]